Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05038332 | Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT]) | recruiting | Phase 2 | 136 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05924672 | Efficacy of Ra-223 in PSMA PET Optimally Selected Patients | active not recruiting | Phase 2 | 2 | University of California, San FranciscoOTHER | 1 | Jan 14, 2026 |
| NCT06059118 | Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04777071 | An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer | active not recruiting | Phase 2 | 141 | University of WashingtonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05570994 | 177Lu-HTK03170 in mCRPC With PSMA Positive Disease | enrolling by invitation | Phase 1 / Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06391034 | Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer | recruiting | Phase 2 | 161 | Robert Bok, MD, PhDOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06970119 | A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 55 | Yunhe Pharmaceutical (Tianjin) Co., LtdOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06866938 | Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer(ReaLuP) | recruiting | Phase 2 | 58 | Hospices Civils de LyonOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT06084338 | Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc | recruiting | Phase 2 | 60 | VA Office of Research and DevelopmentFED | 1 | Dec 31, 2025 | clinicaltrials |
| NCT03809000 | A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery(STEEL) | active not recruiting | Phase 2 | 188 | RTOG Foundation, Inc.OTHER | 2 | Dec 30, 2025 | clinicaltrials |
| NCT07310355 | 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 49 | Chengdu StarRay Therapeutics Co., LtdINDUSTRY | 0 | Dec 30, 2025 | clinicaltrials |
| NCT07310433 | Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer | not yet recruiting | Phase 2 | 60 | Yung NAOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT07300566 | Focal Versus Whole Gland High Dose-Rate Brachytherapy (HDR-BT) Boost to External Beam Radiotherapy in Localized Prostate Cancer: A Phase 2 Randomized Trial(FORWARD) | not yet recruiting | Phase 2 | 58 | Joelle HelouOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT04655365 | Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.(PROSTEP-002) | active not recruiting | Phase 2 | 50 | CHU de Quebec-Universite LavalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT07299292 | Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2) | recruiting | Phase 2 | 60 | SMED Clinical ResearchOTHER | 2 | Dec 23, 2025 | clinicaltrials |
| NCT06155084 | A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients | recruiting | Phase 1 / Phase 2 | 84 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT02452008 | Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03753334 | Effects of EPA in Men With Biochemical Recurrence or Progression of Prostate Cancer.(RCT-EPAII-BCR) | active not recruiting | Phase 2 | 39 | CHU de Quebec-Universite LavalOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07291557 | PSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer | not yet recruiting | Phase 2 | 250 | AHS Cancer Control AlbertaOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03701581 | 4-aminopyridine Treatment for Nerve Injury | recruiting | Phase 2 / Phase 3 | 70 | John ElfarOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT04025372 | INTREPId (INTermediate Risk Erection PreservatIon Trial) | active not recruiting | Phase 2 | 234 | Brigham and Women's HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07282197 | Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019 | not yet recruiting | Phase 2 | 40 | Peking University First HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT03833921 | Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer(APRE) | recruiting | Phase 2 | 130 | Martha MimsOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06353906 | Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer(PRIAM) | recruiting | Phase 2 | 27 | The Netherlands Cancer InstituteOTHER | 2 | Dec 8, 2025 | clinicaltrials |
| NCT07268794 | CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer(CONVERT-HB1) | not yet recruiting | Phase 2 | 112 | Fudan UniversityOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05189457 | First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer | active not recruiting | Phase 2 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05526989 | Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | recruiting | Phase 2 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05893381 | Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)(LUST) | recruiting | Phase 2 | 70 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05786716 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07250542 | A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 2 | 30 | baotai LiangOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07251829 | Neoadjuvant Embolization and Cytoreduction in Prostate Cancer | not yet recruiting | Phase 2 | 35 | Srinivas RamanOTHER | 0 | Nov 26, 2025 | clinicaltrials |
| NCT06400160 | Clinical Trial of TB511 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 12 | Twinpig Biolab, Inc.INDUSTRY | 0 | Nov 25, 2025 | clinicaltrials |
| NCT06126731 | Combination Study of Antibiotics With Enzalutamide (PROMIZE) | recruiting | Phase 1 / Phase 2 | 39 | Institute of Cancer Research, United KingdomOTHER | 2 | Nov 24, 2025 | clinicaltrials |
| NCT02333435 | Effects of EPA on Prostate Cancer Cells Proliferation and Quality of Life(RCT-EPA) | active not recruiting | Phase 2 | 130 | CHU de Quebec-Universite LavalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT07164794 | Memantine Hydrochloride in Prostate Cancer Patients | not yet recruiting | Phase 2 | 15 | Bin XuOTHER | 0 | Nov 19, 2025 | clinicaltrials |
| NCT07163910 | Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study | recruiting | Phase 2 | 93 | baotai LiangOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06536374 | Folate Study in Men With Advanced Prostate Cancer | not yet recruiting | Phase 2 | 50 | University of California, San DiegoOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03541850 | Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery | active not recruiting | Phase 2 | 92 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT05100472 | A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer | active not recruiting | Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT05779943 | Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer | active not recruiting | Phase 2 | 20 | Emory UniversityOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT05540392 | An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues | active not recruiting | Phase 1 / Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT07209878 | 68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI | recruiting | Phase 2 / Phase 3 | 100 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT05869682 | Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy | recruiting | Phase 2 | 210 | City of Hope Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05346848 | Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer(DARIUS) | recruiting | Phase 2 | 62 | Institut BergoniéOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT02972060 | ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer | active not recruiting | Phase 2 | 61 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Sep 19, 2025 | clinicaltrials |
| NCT07179783 | Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) | recruiting | Phase 2 | 28 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT04253483 | Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer | active not recruiting | Phase 2 | 14 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 17, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 16, 2026source: clinicaltrials